STVN
Stevanato Group S.p.A.
NYSE · Healthcare · Medical - Instruments & Supplies · IT
$20.38
−0.78%Aug 9, 2026, 08:04 UTC
Stevanato Group divested its California-based subsidiary Balda C. Brewer, and updated its full-year outlook to reflect this divestiture.
Aug 4, 2026, 10:30 UTC
Stevanato Group reported an 8% increase in revenue to €302.0 million for the second quarter of 2026, with high-value solutions representing 45% of total revenue.
Jul 30, 2026, 10:30 UTC
Stevanato Group announced that liraglutide combination products using its Alina pen injector received marketing authorizations in multiple European countries.
Source:Jul 23, 2026, 06:04 UTC
Zhengchuan Co., Ltd. signed a long-term deep strategic cooperation agreement with SPAMI, a subsidiary of Stevanato Group, in pharmaceutical packaging intelligent manufacturing, standardized operation system construction, and global market expansion.
Source:Jun 8, 2026, 10:30 UTC
Stevanato Group introduced Deora, a pen injector platform for subcutaneous delivery in diabetes and weight management.
Source: